Hot Investor Mandate: China Based Diagnostics CVC Looks for Seed to Series B Opportunities Globally, Focusing on Preclinical to Phase I Therapeutics and In-Development/Clinical Stage Diagnostics but Open to Medical Devices & Digital Health

18 May

Located in Zhengzhou, China, a venture capital firm was founded in 2018 and is the corporate venture arm of Autobio Diagnostics. Through the parent company, funding is dedicated towards early-stage life science companies from Seed to Series B. The initial size of investment is less than $50M USD and the firm aims to invest in 3-5 companies in the upcoming year. The firm is open to global opportunities.

The firm will primarily consider therapeutics and diagnostics and is open to medical devices and digital health. Within therapeutics, the firm is opportunistic and looks at technologies from Pre-clinical to Phase I. The firm has more often invested in cell and gene therapies due to interest in vaccines. Within diagnostics, all modalities from in-development to clinical phases will be considered. The firm has more often invested in in-vitro testing kits and point-of-care testing diagnostics. The firm is opportunistic in the medical devices (in-development to clinical phases) and digital health sectors. While open to all indications, the firm has a particular interest in cancer.

The firm acts as a strategic lead investor and values technology with high potential to go through the approval process.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: